Merck & Co.Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Merck & Co.Diversified pharma anchored by Keytruda, vaccines, and animal health. Entered the obesity pill race in December 2024 by licensing Hansoh's oral small-molecule GLP-1 agonist HS-10535 for $112M upfront and up to $1.9B in milestones; that asset is still preclinical. Its clinical-stage metabolic asset is efinopegdutide, a weekly GLP-1/glucagon co-agonist in Phase 2b for MASH.
All metrics are vertically resized to show how they've changed over time. They're not on the same Y-axis. This chart is meant to compare trends, not values.
Values normalized to 0-100 scale for comparison. Hover for actual values.